Published in J Clin Psychiatry on April 01, 2004
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull (2009) 4.69
Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry (2011) 2.52
Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull (2008) 1.93
Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv (2007) 1.79
Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull (2008) 1.70
Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatr Serv (2007) 1.67
Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res (2006) 1.65
Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract (2005) 1.30
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) (2006) 1.13
Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. BMC Psychiatry (2011) 1.00
Managing suicide risk in patients with schizophrenia. CNS Drugs (2011) 0.92
Unanswered questions in schizophrenia clinical trials. Schizophr Bull (2008) 0.90
Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. Neuropsychiatr Dis Treat (2008) 0.88
Current perspectives in the treatment of resistant schizophrenia. Indian J Psychiatry (2010) 0.86
Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia. Neuropsychiatr Dis Treat (2012) 0.85
How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology (Berl) (2007) 0.85
Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull (2008) 0.85
Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI. Community Ment Health J (2010) 0.84
Antipsychotic polypharmacy in a regional health service: a population-based study. BMC Psychiatry (2012) 0.84
Rethinking antipsychotic formulary policy. Schizophr Bull (2007) 0.80
The appropriateness of routine medication treatment for schizophrenia. Schizophr Bull (2008) 0.80
Elderly patients with schizophrenia and depression: diagnosis and treatment. Clin Schizophr Relat Psychoses (2011) 0.77
Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia. Psychopharmacology (Berl) (2005) 0.76
Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials. BMC Psychiatry (2009) 0.75
Comparison of clozapine response for inpatients in the research setting versus routine clinical practice. Psychiatr Q (2008) 0.75
The Influence of Previous Antipsychotic Polypharmacy Versus Monotherapy on the Effectiveness of Antipsychotic after Switching to Paliperidone Extended-release. Clin Psychopharmacol Neurosci (2013) 0.75
The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA (2003) 34.83
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull (2004) 7.58
The state of science and research in clinical pharmacy. Pharmacotherapy (2006) 7.26
Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry (2005) 6.27
Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA (2006) 6.26
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull (2006) 5.59
Medication augmentation after the failure of SSRIs for depression. N Engl J Med (2006) 5.16
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry (2002) 5.14
Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am (2003) 5.05
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry (2008) 4.98
The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2006) 4.58
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry (2004) 4.46
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull (2003) 4.13
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry (2008) 4.02
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry (2006) 3.90
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry (2008) 3.40
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry (2008) 3.29
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry (2007) 3.26
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 3.21
Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry (2008) 3.13
Estimating Individualized Treatment Rules Using Outcome Weighted Learning. J Am Stat Assoc (2012) 3.13
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry (2006) 3.12
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res (2005) 2.91
A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry (2006) 2.90
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 2.89
Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry (2007) 2.87
Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry (2007) 2.84
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry (2003) 2.83
Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry (2003) 2.82
Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry (2014) 2.81
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry (2002) 2.70
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry (2007) 2.68
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull (2009) 2.61
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. Am J Psychiatry (2011) 2.58
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A (2003) 2.56
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet (2006) 2.55
Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry (2011) 2.52
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry (2005) 2.50
Illness management and recovery: a review of the research. Psychiatr Serv (2002) 2.48
STAR*D: what have we learned? Am J Psychiatry (2007) 2.47
Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study. Am J Psychiatry (2008) 2.42
Barriers to employment for people with schizophrenia. Am J Psychiatry (2006) 2.42
The brief negative symptom scale: psychometric properties. Schizophr Bull (2010) 2.27
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry (2007) 2.26
A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry (2006) 2.23
A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry (2006) 2.21
Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death. JAMA (2010) 2.16
Bipolar I disorder: psychopathology, medical management and dental implications. J Am Dent Assoc (2002) 2.15
The Hartford study of supported employment for persons with severe mental illness. J Consult Clin Psychol (2004) 2.12
Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. Am J Psychiatry (2004) 2.11
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry (2008) 2.10
Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther (2004) 2.10
Alcohol abuse and dependence: psychopathology, medical management and dental implications. J Am Dent Assoc (2003) 2.09
The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep (2007) 2.08
Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv (2007) 1.99
Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder. J Psychiatr Res (2013) 1.99
Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. J Clin Psychiatry (2005) 1.99
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res (2008) 1.97
Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci (2011) 1.96
Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology (2003) 1.96
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res (2008) 1.95
Methodological challenges in constructing effective treatment sequences for chronic psychiatric disorders. Neuropsychopharmacology (2006) 1.93
Early physical and sexual abuse associated with an adverse course of bipolar illness. Biol Psychiatry (2002) 1.93
Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv (2007) 1.93
Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry (2006) 1.90
Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract (2006) 1.89
Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry (2007) 1.88
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry (2011) 1.87
Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry (2011) 1.86
Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophrenia. Arch Gen Psychiatry (2006) 1.86
The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry (2008) 1.86
Genome-wide association study of suicide attempts in mood disorder patients. Am J Psychiatry (2010) 1.85
Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry (2009) 1.82
Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. Am J Psychiatry (2010) 1.82
Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry (2008) 1.81
Gender differences in depression: findings from the STAR*D study. J Affect Disord (2005) 1.80
Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res (2006) 1.80
The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry (2010) 1.80
One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol Psychiatry (2004) 1.79
Prevalence of major depressive episode in CKD. Am J Kidney Dis (2009) 1.79
Effect of age at onset on the course of major depressive disorder. Am J Psychiatry (2007) 1.78